期刊文献+

炎症因子在COVID-19危重症患者中的临床价值探讨 被引量:3

Clinical values of inflammatory factors in critically ill patients with COVID-19
下载PDF
导出
摘要 目的对鄂州市中心医院新型冠状病毒肺炎(COVID-19)危重症及非危重症患者炎症因子进行分析,探讨炎症因子在危重症患者中的表达。方法选取2020年1月24日至2020年2月20日在该院确诊并接受治疗的COVID-19患者135例,分为非危重症组90例,危重症组45例。对两组初次及未次的炎症因子水平变化进行分析和比较。结果白细胞介素(IL)-6、降钙素原(PCT)、白细胞(WBC)、淋巴细胞百分比(L%)在两组间比较,差异均有统计学意义(P<0.05)。高敏C反应蛋白(hs-CRP)、红细胞沉降率比较,差异均无统计学意义(P>0.05)。对危重症死亡患者两次检测结果分析发现,IL-6、PCT、WBC、L%比较,差异有统计学意义(P<0.05),而hs-CRP和红细胞沉降率比较,差异无统计学意义(P>0.05)。对重症转治愈患者两次检测结果分析发现,CRP、WBC比较,差异有统计学意义(P<0.05)。而IL-6、L%、PCT、红细胞沉降率比较,差异无统计学意义(P>0.05)。IL-6、PCT、WBC、L%的受试者工作特征曲线(ROC曲线)下面积分别为0.875、0.749、0.885、0.864,联合检测ROC曲线下面积为0.974。结论IL-6、PCT、WBC、L%在COVID-19危重症患者的临床辅助诊断及病情监测中是较好的指标,联合检测意义更大。 Objective To analyze the inflammatory factors of critically ill and non-critically ill patients with corona virus disease(COVID-19)in the Central Hospital of Ezhou City,and to explore the expression of inflammatory factors in critically ill patients.Methods A total of 135 COVID-19 patients diagnosed and treated in this hospital from January 24 to February 20,2020 were selected and divided into non-critically ill group 90 cases and critically ill group 45 cases.The first and last levels of inflammatory factor were analyzed and compared between the two groups.Results Interleukin(IL)-6,procalcitonin(PCT),white blood cells(WBC)and lymphocyte percentage(L%)were compared between the two groups,and the differences were statistically significant(P<0.05).There was no statistically significant difference in high-sensitivity C-reactive protein(hs-CRP)and erythrocyte sedimentation rate(P<0.05).The two detection results of critically ill patients who died showed that the difference was statistically significant(P<0.05)in IL-6,PCT,WBC and L%,while the difference in hs-CRP and erythrocyte sedimentation rate was not statistically significant(P>0.05).The two results of severely ill converted to cured patients found that the difference between CRP and WBC was statistically significant(P<0.05).However,there was no statistically significant difference in IL-6,L%,PCT and erythrocyte sedimentation rate(P>0.05).The area under the receiver operating characteristic curve(ROC curve)of IL-6,PCT,WBC,L%were 0.875,0.749,0.885,0.864,respectively,and the area under the ROC curve for combined detection was 0.974.Conclusion IL-6,PCT,WBC,and L%are good indicators in the clinical auxiliary diagnosis and condition monitoring of COVID-19 critically ill patients,and joint monitoring is of greater significance.
作者 段秀群 龚国富 张伟 刘思嘉 程炼 DUAN Xiuqun;GONG Guofu;ZHANG Wei;LIU Sijia;CHENG Lian(Department of Clinical Laboratory,Ezhou Central Hospital,Ezhou,Hubei 436000,China;Department of Clinical Laboratory,Ezhou Maternal and Child Health Hospital,Ezhou,Hubei 436099,China)
出处 《检验医学与临床》 CAS 2020年第19期2757-2759,共3页 Laboratory Medicine and Clinic
关键词 新型冠状病毒肺炎 炎症指标 危重症 corona virus disease inflammatory index critically ill
  • 相关文献

参考文献2

二级参考文献132

  • 1Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
  • 2Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
  • 3Wiedermann FJ,Kaneider N,Egger P, et al. Migration of human monocytes in response to procalcitonin [J]. Crit Care Med, 2002 , 30(5): 1112-1117.
  • 4Hoffmann G, Totzke G, Seibel M, et al. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin [J]. Crit Care Med, 2001, 29 (1): 112-126.
  • 5Morgenthaler NG, Struck J, Chancerelle Y,et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection [J]. Horm Metab Res, 2003 , 35 ( 5): 290-295.
  • 6Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin- influence of temperature,storage,anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations [J]. EurJ Clin Chem Clin Biochem, 1997 , 35 ( 8): 597-601.
  • 7Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J]. Ann Emerg Med, 2008 , 52 (1): 48-58.
  • 8Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31 (2): 349-355.
  • 9Hirakata Y,Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2008 , 61 (2): 170-174.
  • 10Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department : an observational study[J]. Crit Care, 2(XM, 8 (1): R12-20.

共引文献686

同被引文献21

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部